SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC US FDA Inspections 8-K Filing 2024 - Clinical Trial Update Shuttle Pharmaceuticals announced that it has finalized agreements with six locations to conduct a Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, with patient screening currently underway.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC